UK markets close in 34 minutes

Calidi Biotherapeutics, Inc. (CLDI)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
0.2304-0.0056 (-2.37%)
As of 10:37AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 11.55M
Enterprise value 16.84M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)50.83
Price/book (mrq)N/A
Enterprise value/revenue 49.42
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.57
52-week change 3-97.71%
S&P500 52-week change 326.27%
52-week high 313.7900
52-week low 30.1440
50-day moving average 30.4414
200-day moving average 32.8313

Share statistics

Avg vol (3-month) 31.07M
Avg vol (10-day) 32.39M
Shares outstanding 548.96M
Implied shares outstanding 648.96M
Float 822.07M
% held by insiders 154.95%
% held by institutions 17.86%
Shares short (30 Apr 2024) 445.57k
Short ratio (30 Apr 2024) 40.02
Short % of float (30 Apr 2024) 40.12%
Short % of shares outstanding (30 Apr 2024) 40.09%
Shares short (prior month 28 Mar 2024) 4149.02k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-287.25%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -28.6M
Net income avi to common (ttm)-29.22M
Diluted EPS (ttm)-1.7300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.95M
Total cash per share (mrq)0.05
Total debt (mrq)7.24M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.42
Book value per share (mrq)-0.23

Cash flow statement

Operating cash flow (ttm)-26.98M
Levered free cash flow (ttm)-43.96M